title: [Problems produced by the use of antitubercular agents in a reference service for HIV/AIDS in Abidjan (Côte d'Ivoire)].
abstract: This study reports on the experience using antituberculosis drugs in a HIV/AIDS reference service in Abidjan during a 64 month period. Prevalence of tuberculosis is 1.9% out of a total of 23,957 patients. The annual incidence rate increased slowly from 0.9% in 1990 to 3.5% in 1995. Seropositivity to HIV is 90.8%. Predominant locations of tuberculosis are pulmonary (60.3%), extrapulmonary (19.7%) and multifocal or disseminated (20%). The average period of diagnosis (9.9 days) and average duration of antituberculosis treatment in hospital (11.8 days) are similar whatever the serological status and the location of the infection may be. However, the mortality rate is more important in HIV positive patients (39.7%) than in HIV negative (17.6%) p = 0.01. The decision to treat is taken by infectiologists only in 88% of the cases, by pneumologists only in 2.5%, and both by infectiologists and pneumologists in 9.5%. Side-effects due to antituberculosis drugs were noticed in 19 patients leading to an interruption of the treatment in 10 cases. The authors recommend that health personnel be trained for the management of tuberculosis.
authors.affiliation: Clinique des maladies infectieuses, CHU Treichville, Abidjan, Côte d'Ivoire.
authors.forename: A
authors.initials: A
authors.lastname: Kakou
authors.forename: S
authors.initials: S
authors.lastname: Eholie
authors.forename: B
authors.initials: B
authors.lastname: Yao
authors.forename: M
authors.initials: M
authors.lastname: Coulibaly
authors.forename: E
authors.initials: E
authors.lastname: Ehui
authors.forename: E
authors.initials: E
authors.lastname: Bissagnéné
authors.forename: E
authors.initials: E
authors.lastname: Aoussi
authors.forename: A
authors.initials: A
authors.lastname: Kadio
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000009:adverse effects*; D007560:Cote d'Ivoire / Q000453:epidemiology; D005260:Female; D006679:HIV Seropositivity; D006801:Humans; D008297:Male; D008875:Middle Aged; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D000995:Antitubercular Agents